Drugs / ovarian cancer peptide vaccine
last change Jun 2007 re-read 2 minutes ago

ovarian cancer peptide vaccine

Vaccine

Developed for
ovarian cancer · primary peritoneal carcinoma
Investigated by
National Cancer Institute (NCI) · University of Virginia

Trials 1 · a red edge is where a trial was stopped

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00091273 Jun 2004 → Feb 2006 ovarian cancer, primary peritoneal carcinoma University of Virginia Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ovarian cancer peptide vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00091273
Modality Vaccine “Peptide VaccineNCT00091273
Route Other “subcutaneously and intradermally” NCT00091273
Route Subcutaneous subcutaneously and intradermally” NCT00091273